A strategy of symptom-limited exercise with regadenoson-as-needed for stress myocardial perfusion imaging: A randomized controlled trial

Journal of Nuclear Cardiology

Volumn 20, Issue 2, 2013, Pages 185-196

  Parker, Matthew W ^a,b   Morales, Donna Chelle ^a,b   Slim, Hanna B ^a,b   Ahlberg, Alan W ^b   Katten, Deborah M ^b   Cyr, Giselle ^b   Mathur, Shishir ^a,b   Ardestani, Afrooz ^a,b   Barmpouletos, Dimitrios ^a,b   Iyah, Geeta Swamy ^a,b   Borer, Steven M ^b   Heller, Gary V ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

A2A adenosine receptor agonists; exercise: stress testing; image quality; myocardial perfusion imaging: SPECT

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; AMINOPHYLLINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; REGADENOSON; SALBUTAMOL; TECHNETIUM 99M; THALLIUM 201; TRACER;

ADULT; ARTICLE; BRONCHOSPASM; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; EXERCISE; FEMALE; FLUSHING; FUNCTIONAL STATUS; HEART ARRHYTHMIA; HEART HEMODYNAMICS; HEART RATE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTENSION; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE QUALITY; MAJOR CLINICAL STUDY; MALE; METABOLIC EQUIVALENT; MYOCARDIAL PERFUSION IMAGING; NAUSEA; PHARMACOLOGIC STRESS TESTING; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUPRAVENTRICULAR TACHYCARDIA; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TREADMILL EXERCISE; TREATMENT INDICATION;

ADENOSINE A2 RECEPTOR AGONISTS; CORONARY ARTERY DISEASE; EXERCISE TEST; FEMALE; HUMANS; IMAGE ENHANCEMENT; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; PURINES; PYRAZOLES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VASODILATOR AGENTS;

EID: 84879506577     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-012-9641-7     Document Type: Article

References (24)

1. Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol 2003;42:1318-33.
2. Phillips L, Wang JW, Pfeffer B, Gianos E, Fisher D, Shaw LJ, et al. Clinical role of the Duke Activity Status Index in the selection of the optimal type of stress myocardial perfusion imaging study in patients with known or suspected ischemic heart disease. J Nucl Cardiol 2011;18:1015-20.
3. Iskandrian AS, Heo J, Kong B, Lyons E. Effect of exercise level on the ability of thallium-201 tomographic imaging in detecting coronary artery disease: Analysis of 461 patients. J Am Coll Cardiol 1989;14:1477-86.
4. Heller GV, Ahmed I, Tilkemeier PL, Barbour MM, Garber CE. Comparison of chest pain, electrocardiographic changes and thallium-201 scintigraphy during varying exercise intensities in men with stable angina pectoris. Am J Cardiol 1991;68:569-74.
5. Verzijlbergen JF, Vermeersch PH, Laarman GJ, Ascoop CA. Inadequate exercise leads to suboptimal imaging. Thallium-201 myocardial perfusion imaging after dipyridamole combined with low-level exercise unmasks ischemia in symptomatic patients with non-diagnostic thallium-201 scans who exercise submaximally. J Nucl Med 1991;32:2071-8.
6. Hendel RC. Exercise and pharmacologic stress testing. In: Heller GV, Hendel RC, editors. Nuclear cardiology: Practical applications. 2nd ed. New York: McGraw Hill Medical; 2011. p. 53-69.
7. Elliott MD, Holly TA, Leonard SM, Hendel RC. Impact of an abbreviated adenosine protocol incorporating adjunctive treadmill exercise on adverse effects and image quality in patients undergoing stress myocardial perfusion imaging. J Nucl Cardiol 2000;7:584-9.
8. Thomas GS, Prill NV, Majmundar H, Fabrizi RR, Thomas JJ, Hayashida C, et al. Treadmill exercise during adenosine infusion is safe, results in fewer adverse reactions, and improves myocardial perfusion image quality. J Nucl Cardiol 2000;7:439-46.
9. Pennell DJ, Mavrogeni SI, Forbat SM, Karwatowski SP, Underwood SR. Adenosine combined with dynamic exercise for myocardial perfusion imaging. J Am Coll Cardiol 1995;25:1300-9.
10. Jamil G, Ahlberg AW, Elliott MD, Hendel RC, Holly T, McGill CC, et al. Impact of limited treadmill exercise on adenosine Tc-99m sestamibi single-photon emission computed tomographic myocardial perfusion imaging in coronary artery disease. Am J Cardiol 1999;84:400-3.
11. Samady H, Wackers FJT, Joska TM, Zaret BL, Jain D. Pharmacologic stress perfusion imaging with adenosine: Role of simultaneous low-level treadmill exercise. J Nucl Cardiol 2002;9:188-96.
12. Vitola JV, Brambatti JC, Caligaris F, Lesse CR, Nogueira PR, Joaquim AI, et al. Exercise supplementation to dipyridamole prevents hypotension, improves electrocardiogram sensitivity, and increases heart-to-liver activity ratio on Tc-99m sestamibi imaging. J Nucl Cardiol 2001;8:652-9.
13. Casale PN, Guiney TE, Strauss HW, Boucher CA. Simultaneous low level treadmill exercise and intravenous dipyridamole stress thallium imaging. Am J Cardiol 1988;62:799-802.
14. Stern S, Greenberg ID, Corne RA. Quantification of walking exercise required for improvement of dipyridamole thallium-201 image quality. J Nucl Med 1992;33:2061-6.
15. Jaroudi al W, Iskandrian AE. Regadenoson: A new myocardial stress agent. J Am Coll Cardiol 2009;54:1123-30.
16. Thomas GS, Thompson RC, Miyamoto MI, Ip TK, Rice DL, Milikien D, et al. The RegEx trial: A randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2009;16:63-72.
17. Kwon DH, Cerqueira MD, Young R, Houghtaling P, Lieber E, Menon V, et al. Lessons from regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: Initial clinical experience in 1263 patients. J Nucl Cardiol 2010;17:853-7.
18. Hlatky MA, Boineau RE, Higginbotham MB, Lee KL, Mark DB, Califf RM, et al. A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol 1989;64:651-4.
19. Holly TA, Abbott BG, Al-Mallah M, Calnon DA, Cohen MC, DiFilippo FP, et al. Single photon-emission computed tomography. Journal of Nuclear Cardiology 2010;17:941-73.
20. Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE, ADVANCE-MPI Trial Investigators. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 2008;1:307-16.
21. Leaker BR, O'Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS, et al. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: A randomized, double-blind, placebo-controlled trial. J Nucl Cardiol 2008;15:329-36.
22. Thomas GS, Tammelin BR, Schiffman GL, Marquez R, Rice DL, Milikien D, et al. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol 2008;15:319-28.
23. Prenner BM, Bukofzer S, Behm S, Feaheny K, McNutt BE. A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol 2012;19:681-92.
24. Mahmarian JJ, Cerqueira MD, Iskandrian AE, Bateman TM, Thomas GS, Hendel RC, et al. Regadenoson induces comparable left ventricular perfusion defects as adenosine: A quantitative analysis from the ADVANCE MPI 2 trial. JACC Cardiovasc Imaging 2009;2:959-68.